What the FDA labels say about taking them together
Fluconazole and tofacitinib
Fluconazole's FDA label (Fluconazole) of April 2, 2026 names tofacitinib in its drug interactions section, and tofacitinib's label names fluconazole too. The fluconazole label: “Drug Interaction Studies.) Tofacitinib Systemic exposure to tofacitinib is increased when tofacitinib is coadministered with fluconazole.”
Check it at the source: the fluconazole FDA label on DailyMed (effective April 7, 2026, Zydus Pharmaceuticals (USA) Inc.); the tofacitinib FDA label on DailyMed (effective July 13, 2026, U.S. Pharmaceuticals).
What does the fluconazole label say about tofacitinib?
Fluconazole label (Mylan Pharmaceuticals Inc., April 2, 2026), drug interactionsDrug Interaction Studies .) Tofacitinib Systemic exposure to tofacitinib is increased when tofacitinib is coadministered with fluconazole.
Source: FDA drug label (Fluconazole, NDA020090), Mylan Pharmaceuticals Inc., effective April 2, 2026 (SPL set 737e0fac-a2d2-4053-a0d7-edbfb6248f69), via openFDA
Source: FDA drug label (fluconazole), Zydus Pharmaceuticals (USA) Inc., effective April 7, 2026 (SPL set d1364455-1537-46d4-b093-38cca3be778f), via openFDA; the full label on DailyMed
What does the tofacitinib label say about fluconazole?
Tofacitinib label, drug interactionsClinically Significant Interactions Affecting XELJANZ/XELJANZ XR When Concomitantly Used with Other Drugs Strong CYP3A4 Inhibitors (e.g., ketoconazole) Clinical Impact Increased exposure to tofacitinib Intervention Dosage modification of XELJANZ/XELJANZ XR is recommended [see Dosage and Administration (2), Clinical Pharmacology, Figure 3 (12.3) ] Moderate CYP3A4 Inhibitors Concomitantly Used with Strong CYP2C19 Inhibitors (e.g., fluconazole) Clinical Impact Increased exposure to tofacitinib Intervention Dosage modification of XELJANZ/XELJANZ XR is recommended [see Dosage and Administration (2), Clinical Pharmacology, Figure 3 (12.3) ] Strong CYP3A4 Inducers (e.g., rifampin) Clinical Impact …
Source: FDA drug label (XELJANZ), NDA203214 (Pf Prism Cv), as published by U.S. Pharmaceuticals, effective July 13, 2026 (SPL set 68e3d6b2-7838-4d2d-a417-09d919b43e13), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Fluconazole | Tofacitinib | |
|---|---|---|
| Labeled for | Fungal infections, Urinary tract infections | Rheumatoid arthritis, Crohn's disease and ulcerative colitis |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.380 per tablet 200 mg tablet | $0.573 per tablet 5 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once